JP2020503341A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503341A5
JP2020503341A5 JP2019536014A JP2019536014A JP2020503341A5 JP 2020503341 A5 JP2020503341 A5 JP 2020503341A5 JP 2019536014 A JP2019536014 A JP 2019536014A JP 2019536014 A JP2019536014 A JP 2019536014A JP 2020503341 A5 JP2020503341 A5 JP 2020503341A5
Authority
JP
Japan
Prior art keywords
group
substituted
groups
disease
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536014A
Other languages
English (en)
Japanese (ja)
Other versions
JP6901569B2 (ja
JP2020503341A (ja
Filing date
Publication date
Priority claimed from CN201611260514.6A external-priority patent/CN108264535A/zh
Application filed filed Critical
Publication of JP2020503341A publication Critical patent/JP2020503341A/ja
Publication of JP2020503341A5 publication Critical patent/JP2020503341A5/ja
Application granted granted Critical
Publication of JP6901569B2 publication Critical patent/JP6901569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536014A 2016-12-30 2017-12-29 抗うつ化合物およびその製造方法と使用 Active JP6901569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611260514.6 2016-12-30
CN201611260514.6A CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
PCT/CN2017/120134 WO2018121770A1 (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2020503341A JP2020503341A (ja) 2020-01-30
JP2020503341A5 true JP2020503341A5 (https=) 2021-05-27
JP6901569B2 JP6901569B2 (ja) 2021-07-14

Family

ID=62707894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536014A Active JP6901569B2 (ja) 2016-12-30 2017-12-29 抗うつ化合物およびその製造方法と使用

Country Status (5)

Country Link
US (1) US11142543B2 (https=)
EP (1) EP3564253B1 (https=)
JP (1) JP6901569B2 (https=)
CN (2) CN108264535A (https=)
WO (1) WO2018121770A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
WO2020259612A1 (zh) * 2019-06-26 2020-12-30 中国科学院上海药物研究所 一种抗抑郁甾体化合物
CN113831381A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种用于治疗抑郁症的甾体化合物
CN113831382A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种甾体化合物
CN113292629B (zh) * 2021-06-21 2022-04-26 西南民族大学 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用
EP4477225A4 (en) * 2022-02-18 2026-01-21 Beijing Phytovent Pharmaceutical Tech Co Ltd USE OF A SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND ASSOCIATED PHARMACEUTICAL COMPOSITION
CN116621912A (zh) * 2022-02-18 2023-08-22 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
WO2005051381A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
WO2005051380A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
US20050245495A1 (en) * 2004-04-07 2005-11-03 Chen Zhao Azacyclosteroid histamine-3 receptor ligands
TW200621244A (en) 2004-08-19 2006-07-01 Vertex Pharma Modulators of muscarinic receptors
CN101214253B (zh) 2008-01-07 2011-09-21 中国人民解放军第二军医大学 知母皂苷b-ⅱ用于制备抗抑郁产品的用途
EP2262789A1 (en) 2008-03-05 2010-12-22 F. Hoffmann-La Roche AG 2-aminoquinolines
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
US20170129915A1 (en) 2014-04-25 2017-05-11 Resilio Company Limited Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2020503341A5 (https=)
JP2020023528A5 (https=)
JP2019524883A5 (https=)
JP2020510091A5 (https=)
JP2018070614A5 (https=)
CN106660974B (zh) 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
JP2018504437A5 (https=)
JP2016512531A5 (https=)
JP2006506466A5 (https=)
JP2007529421A5 (https=)
JP2019529490A5 (https=)
JP2018503663A5 (https=)
JP2019522055A5 (https=)
JPWO2022222921A5 (https=)
JP2009526034A5 (https=)
JP2013541503A5 (https=)
JP2020529994A5 (https=)
JP2019518050A5 (https=)
JP2015508092A5 (https=)
RU2009142430A (ru) Производные триазолопиридинкарбоксамидов, их получение и применение в терапии
JP2019515908A5 (https=)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2019520344A5 (https=)
JP2019526546A5 (https=)
JP2019528279A (ja) キナーゼ阻害物質化合物、組成物、及びがんの治療方法